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MRI is  a  key  tool  for  diagnosing,  monitoring,  and  in  the  prognostic  stratiﬁcation  of  most
cardiomyopathies  [1].  It  permits  exhaustive  study  of  systolic  and  diastolic  function  and  pre-
cise  tissue  characterisation,  particularly  of  ﬁbrosis,  using  delayed-enhancement  sequences
(DE)  [2,3]. We  report  here  the  case  of  a  79-year-old  female  patient  of  Caucasian  origin
referred  for  MRI  to  investigate  disabling  dyspnoea  in  the  context  of  a  hypereosinophilic
syndrome.
Observation
This  patient  was  referred  to  us  for  investigation  of  New  York  Heart  Association  (NYHA)  grade
3  dyspnoea  associated  with  a  hypereosinophilic  syndrome,  with  no  other  blood  abnormal-
ity.  The  ECG  showed  incomplete  right  bundle  branch  block.  Cardiac  MRI  was  performed  in
this  patient  with  cardiac  gating,  in  regular  sinus  rhythm  at  70  bpm.  The  left  ventricular
ejection  fraction  (LVEF)  was  subnormal  at  50%  with  discrete  global  hypokinesis  and  a  small
left  ventricle  (LV)  (normalised  end  diastolic  volume  =  63  mL/m2, normal  41—81  mL/m2).
Right  ventricular  function  (RV)  was  normal.  First  pass  perfusion  showed  diffuse  subendo-
cardial  hypoperfusion  in  the  LV  and  RV  (Fig.  1  a,  b,  c,  arrows).  DE  sequences  showed  diffuse
subendocardial  enhancement  involving  both  the  LV  and  RV,  without  vascular  systematisa-
tion,  typical  of  endomyocardial  ﬁbrosis  (Fig.  1  d,  f,  arrows).  They  also  showed  the  presence
of  a  thrombus  at  the  apex  of  the  LV  and  RV  (Fig.  1  e,  f,  arrowheads).  The  atria  were  dilated
with  a  4-chamber  view  of  the  left  atrium  measuring  27  cm2 at  the  end  of  systole  (N  <  24
cm2).
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Figure 1. Cardiac MRI: ﬁrst passage perfusion sequences (a, b, c) showing hypoperfusion as a hyposignal in the apices of the ventricles
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s(arrows); late enhancement sequences (d, e, f) showing diffuse s
thrombi in the apices of the ventricles (arrowheads).
Discussion
Endomyocardial  ﬁbrosis  is  a  condition  belonging  to  the  group
of  restrictive  cardiomyopathies  ﬁrst  described  in  the  1940s
in  Uganda  by  Davies  [4].  It  is  characterised  by  the  depo-
sition  of  ﬁbrous  tissue  in  the  endocardium,  predominantly
in  the  ﬁlling  routes  and  the  apices  of  the  right  and  left
ventricles  [5,6]. Although  this  is  a  condition  that  was  origi-
nally  described  in  tropical  and  subtropical  regions,  cases  are
also  regularly  described  in  Europe.  Endomyocardial  ﬁbro-
sis  lesions  as  described  by  Davies  resemble  the  ﬁbroplastic
parietal  endocarditis  described  by  Löfﬂer  in  temperate
countries,  which  is  found  in  idiopathic  or  secondary  hypere-
osinophilic  syndromes  such  as  Churg-Strauss  syndrome  [7,8].
The  term  endomyocardial  ﬁbrosis  is  used  in  the  literature  to
describe  one  or  other  of  these  entities.  The  lesions  described
in  endomyocardial  ﬁbrosis  also  resemble  those  found  in  car-
cinoid  heart  disease  [9].  This  is  because  of  the  importance  of
the  role  played  by  eosinophils  and  serotonin  in  the  pathologi-
cal  process.  The  mechanisms  of  this  disease  are  still  debated
and  other  causes  have  been  suggested:  infections  (tox-
oplasmosis,  rheumatoid  arthritis,  malaria,  helminthiasis),
allergies  (hypereosinophilia,  autoimmunity),  malnutrition,
and  toxic  agents.  In  practice,  transthoracic  echocardiogra-
phy  is  the  ﬁrst  examination  to  be  undertaken  and  provides  an
accurate  assessment  of  systolic  and  diastolic  function.  Nev-
ertheless,  it  has  limitations  for  characterisation  of  tissues
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adocardial enhancement (arrows) associated with the presence of
nd differential  diagnosis  of  restrictive  cardiomyopathies.
RI,  however,  plays  a  key  role  in  the  diagnosis  and  progno-
is  of  this  condition,  although  few  data  have  been  reported
n  the  literature  [10—12]. It  provides  precise  morphological
valuation,  usually  characterised  by  restriction  with  non-
ilated  or  small  ventricles,  as  in  the  case  reported  here.
he  atria  are  often  increased  in  size  because  of  the  severe
iastolic  dysfunction  with  a  restrictive  disorder  [2].  This
iastolic  dysfunction  is  the  cause  of  the  patients’  symptoms
ho  often  have  disabling  NYHA  grade  3  or  4  dyspnoea.  The
E  sequences  conﬁrm  the  diagnosis  by  showing  typical  DE,
imited  to  the  subendocardium  and  extending  from  the  sub-
alvular  regions  to  the  apices  of  the  two  ventricles,  where
t  usually  predominates.  A  key  element  is  that  the  enhance-
ent  is  not  distributed  in  the  vessels  and,  in  most  cases,  is
ot  accompanied  by  myocardial  thinning.  A  thrombus  is  fre-
uently  present  at  the  apex  of  the  LV  and/or  RV  and,  here
gain,  MRI  plays  a  key  role  in  providing  this  diagnosis,  which
s  often  underestimated  by  echocardiography.  Recently,  a
rognostic  role  for  MRI  has  also  been  suggested  [11]. The
tandard  treatment,  indicated  in  patients  with  NYHA  grades
 or  4,  is  surgical  resection  of  areas  of  endomyocardial  ﬁbro-
is  [5,6]. MRI  may  in  the  future  help  in  planning  surgery  and
onitoring  its  efﬁcacy.  In  the  case  of  our  patient,  it  was  dif-
cult  to  envisage  surgical  treatment  given  her  extremely
ragile  condition.  Medical  treatment  combining  diuretics
nd  converting  enzyme  inhibitors  improved  the  dyspnoea.
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ollow-up  MRI  after  one  year  (not  shown)  showed  stable
unctional  abnormalities  and  delayed  enhancement.  It  also
howed  marked  regression  of  the  apical  thrombi  under  anti-
oagulant  treatment.
onclusion
ndomyocardial  ﬁbrosis  is  a  rare  disease  in  temperate
ountries,  and  falls  within  the  differential  diagnosis  of
estrictive  cardiomyopathies.  Cardiac  MRI  provides  a  precise
etiological  diagnosis  for  patients  referred  with  suspected
ndomyocardial  ﬁbrosis,  and  could  help  prognostic  strati-
cation  and  in  planning  therapeutic  procedures  for  these
atients.
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